FOLFOXIRI‐Bevacizumab or FOLFOX‐Panitumumab in Patients with Left‐Sided RAS/BRAF Wild‐Type Metastatic Colorectal Cancer: A Propensity Score‐Based Analysis

BACKGROUND: Doublets plus anti‐epidermal growth factor receptors (EGFRs) are the preferred upfront option for patients with left‐sided RAS/BRAF wild‐type metastatic colorectal cancer (mCRC). Initial therapy with FOLFOXIRI‐bevacizumab is superior to doublets plus bevacizumab independently from primar...

詳細記述

保存先:
書誌詳細
出版年:Oncologist
主要な著者: Pietrantonio, Filippo, Fucà, Giovanni, Rossini, Daniele, Schmoll, Hans‐Joachim, Bendell, Johanna C., Morano, Federica, Antoniotti, Carlotta, Corallo, Salvatore, Borelli, Beatrice, Raimondi, Alessandra, Marmorino, Federica, Niger, Monica, Boccaccino, Alessandra, Masi, Gianluca, Lonardi, Sara, Boni, Luca, de Braud, Filippo, Di Bartolomeo, Maria, Falcone, Alfredo, Cremolini, Chiara
フォーマット: Artigo
言語:Inglês
出版事項: John Wiley & Sons, Inc. 2021
主題:
Gastrointestinal Cancer
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC8018298/
https://ncbi.nlm.nih.gov/pubmed/33336844
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13642
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料